Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 156 Jul 27 – Oct 24, 2026
- Disclosed funding
- $5.9B 121 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| AT Adjuvia TherapeuticsCompany profile Adjuvia develops oral nanoparticle therapies intended to address mitochondrial dysfunction, starting with its ATI-105 program for rare diseases. Adjuvia develops oral nanoparticle therapies intended to address mitochondrial dysfunction, starting with its ATI-105 program for rare diseases. | $8M | Seed | Biotech | United States | Investors | |
| TB Developing nerve-targeted imaging technologies for surgery. | Undisclosed | Series A | Biotech | United States | Investors | |
| CB CORE BiomedicineCompany profile Developing the next generation of precision medicines by going beyond genomics. Developing the next generation of precision medicines by going beyond genomics. | $21M | Series A | Biotech | United States | Investors | |
| TP Torrey Pines MedicineCompany profile Develops ultra-long-acting peptide therapeutics for obesity, diabetes, and metabolic diseases Develops ultra-long-acting peptide therapeutics for obesity, diabetes, and metabolic diseases | Undisclosed | Pre-SeedPre-seed | Biotech | China | Investors | |
| VD Vivid DxCompany profile Rapid infectious disease testing helping hospitals identify pathogens and guide antibiotic decisions Rapid infectious disease testing helping hospitals identify pathogens and guide antibiotic decisions | $15M | Seed | Biotech, Healthtech | United Kingdom | Investors | |
| M MiraeCompany profile AI-driven continuous care platform for autoimmune disease and other complex chronic conditions AI-driven continuous care platform for autoimmune disease and other complex chronic conditions | $5.4M | Seed | Biotech, Healthtech | United Kingdom | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 27, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
9rounds3led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
5rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.